Education
About Us
Working with TipRanks
Follow Us
Alumis Inc. (ALMS)
NASDAQ:ALMS
ALMS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.18 - $13.53
Previous CloseN/A
Volume29.29K
Average Volume (3M)1.14M
Market Cap
$270.40M
Enterprise Value$170.10M
Total Cash (Recent Filing)$112.18M
Total Debt (Recent Filing)$32.08M
Price to Earnings (P/E)―
Beta-3.24
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.45
Shares Outstanding47,222,420
10 Day Avg. Volume454,937
30 Day Avg. Volume1,140,008
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$21.50Price Target Upside332.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Alumis Inc. News
PremiumCompany Announcements
Alumis Inc. Reports 2024 Results and Strategic Merger
---
Bulls Say, Bears Say
Bulls Say
Financial StrengthThe cash infusion from the deal extends Alumis Inc.'s operational cash runway through the planned topline data readout of the ongoing Phase 3 ONWARD program of ESK-001 in psoriasis.
Partnership And CollaborationThe collaboration and license agreement with Kaken Pharmaceutical for the development and commercialization of ESK-001 in Japan is a significant boost for Alumis Inc.
Product DifferentiationESK-001 could also steal market share from biologics.
Bears Say
Financial PerformanceLowering price target based on impact of increased projected operating expenses on valuation.
Regulatory And Development RisksRisks include inability to advance ESK-001 into pivotal trials in a timely fashion, failure of ESK-001 to show compelling efficacy, and delays in completing regulatory submissions in key territories.
---
Ownership Overview
61.57% Insiders
2.05% Mutual Funds
<0.01% Other Institutional Investors
32.96% Public Companies and
Individual Investors
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $3.18 and its highest was $13.53 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $270.40M.
When is Alumis Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on Nov 13, 2024. The company reported -$1.73 earnings per share for the quarter, beating the consensus estimate of -$1.778 by $0.048.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 47,222,420 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$1.73 in its last earnings report, beating expectations of -$1.778. Following the earnings report the stock price went down -18.307%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
---
Alumis Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.50 (332.60% Upside)
$21.50 (332.60% Upside)
Blogger Sentiment
Bearish
ALMS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 35.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $230.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.4%
Last 30 Days ▲ 27.0%
Last 30 Days ▲ 27.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-198.66%
Trailing 12-Months
Asset Growth
280.52%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
---
ALMS Stock 12 Month Forecast
Average Price Target
$21.50
▲(332.60% Upside)
Technical Analysis
Celcuity
―
Oric Pharmaceuticals
―
Erasca
―
Maze Therapeutics, Inc.
―
Sionna Therapeutics, Inc.
―
Best Analysts Covering ALMS
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-31.65%
reiterated a buy rating 3 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -31.65% per trade.
---